Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | REN | P00797 | 9/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.33 |
| ▸ | ITGAV | P06756 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4301642 | 0.82 | CYP11B2 (0.38) | CYP11B2ADORA1KDM4EMEN1KMT2A | |
| SCHEMBL4296426 | 0.81 | ELANE (0.43) | REN | |
| Hydrochloric Acid SCHEMBL4291159 | 0.80 | ELANE (0.43) | REN | |
| SCHEMBL4753442 | 0.79 | KMO (0.50) | RENKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL4290999 | 0.79 | KMO (0.50) | RENKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL4303724 | 0.76 | KDM4E (0.36) | RENKDM4EMEN1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL4290890 | 0.75 | KDM4E (0.38) | RENKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL15997886 | 0.74 | CYP11B2 (0.48) | CYP11B2KDM4EMEN1KMT2A | |
| SCHEMBL15987446 | 0.74 | CYP11B2 (0.48) | CYP11B2ADORA1KDM4EMEN1KMT2A | |
| SCHEMBL4294395 | 0.73 | KMO (0.48) | RENKDM4EMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | CYP11B2 6/4885REN 1/4885PARP1 3523/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | CYP11B2 6/4885REN 1/4885PARP1 3523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.